{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:06:20Z","timestamp":1792724780337,"version":"4.5.0"},"reference-count":48,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T00:00:00Z","timestamp":1691971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Science and Technology Agency (JST)","award":["JPMJMS2021"],"award-info":[{"award-number":["JPMJMS2021"]}]},{"name":"Japan Science and Technology Agency (JST)","award":["21lm0203005j0005 (A145)"],"award-info":[{"award-number":["21lm0203005j0005 (A145)"]}]},{"name":"Japan Science and Technology Agency (JST)","award":["22ym0126807j0001 (A160)"],"award-info":[{"award-number":["22ym0126807j0001 (A160)"]}]},{"name":"Japan Science and Technology Agency (JST)","award":["21am0401024h0003"],"award-info":[{"award-number":["21am0401024h0003"]}]},{"name":"Japan Science and Technology Agency (JST)","award":["21K07237"],"award-info":[{"award-number":["21K07237"]}]},{"name":"Japan Science and Technology Agency (JST)","award":["21H02782"],"award-info":[{"award-number":["21H02782"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["JPMJMS2021"],"award-info":[{"award-number":["JPMJMS2021"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["21lm0203005j0005 (A145)"],"award-info":[{"award-number":["21lm0203005j0005 (A145)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["22ym0126807j0001 (A160)"],"award-info":[{"award-number":["22ym0126807j0001 (A160)"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["21am0401024h0003"],"award-info":[{"award-number":["21am0401024h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["21K07237"],"award-info":[{"award-number":["21K07237"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development (AMED)","doi-asserted-by":"publisher","award":["21H02782"],"award-info":[{"award-number":["21H02782"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["JPMJMS2021"],"award-info":[{"award-number":["JPMJMS2021"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["21lm0203005j0005 (A145)"],"award-info":[{"award-number":["21lm0203005j0005 (A145)"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["22ym0126807j0001 (A160)"],"award-info":[{"award-number":["22ym0126807j0001 (A160)"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["21am0401024h0003"],"award-info":[{"award-number":["21am0401024h0003"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["21K07237"],"award-info":[{"award-number":["21K07237"]}]},{"name":"Japan Society for the Promotion of Science (JSPS)","award":["21H02782"],"award-info":[{"award-number":["21H02782"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Chimeric-antigen-receptor (CAR) T-cell therapy for CD19-expressing B-cell malignancies is already widely adopted in clinical practice. On the other hand, the development of CAR-T-cell therapy for T-cell malignancies is in its nascent stage. One of the potential targets is CD26, to which we have developed and evaluated the efficacy and safety of the humanized monoclonal antibody YS110. We generated second (CD28) and third (CD28\/4-1BB) generation CD26-targeted CAR-T-cells (CD26-2G\/3G) using YS110 as the single-chain variable fragment. When co-cultured with CD26-overexpressing target cells, CD26-2G\/3G strongly expressed the activation marker CD69 and secreted IFNgamma. In vitro studies targeting the T-cell leukemia cell line HSB2 showed that CD26-2G\/3G exhibited significant anti-leukemia effects with the secretion of granzymeB, TNF\u03b1, and IL-8, with 3G being superior to 2G. CD26-2G\/3G was also highly effective against T-cell lymphoma cells derived from patients. In an in vivo mouse model in which a T-cell lymphoma cell line, KARPAS299, was transplanted subcutaneously, CD26-3G inhibited tumor growth, whereas 2G had no effect. Furthermore, in a systemic dissemination model in which HSB2 was administered intravenously, CD26-3G inhibited tumor growth more potently than 2G, resulting in greater survival benefit. The third-generation CD26-targeted CAR-T-cell therapy may be a promising treatment modality for T-cell malignancies.<\/jats:p>","DOI":"10.3390\/cells12162059","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T10:20:14Z","timestamp":1692008414000},"page":"2059","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies"],"prefix":"10.3390","volume":"12","author":[{"given":"Eiji","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5367-406X","authenticated-orcid":false,"given":"Yusuke","family":"Kamihara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6218-519X","authenticated-orcid":false,"given":"Akinori","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0961-6253","authenticated-orcid":false,"given":"Shohei","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2727-7275","authenticated-orcid":false,"given":"Ryo","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Iwao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Shizuoka Hospital, Izunokuni City, Shizuoka 410-2211, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1512-0753","authenticated-orcid":false,"given":"Takeshi","family":"Susukida","sequence":"additional","affiliation":[{"name":"Division of Host Defences, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Ozawa","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Adachi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8740-5371","authenticated-orcid":false,"given":"Hiroyuki","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam H.","family":"Dang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Florida, Gainesville, FL 32610-0275, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pathology, Saitama Medical University, 38 Morohongo, Moroyama, Saitama 3500495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-1171","authenticated-orcid":false,"given":"Yoshihiro","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Division of Host Defences, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikao","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/B978-0-12-385855-9.00003-5","article-title":"Dipeptidyl Peptidase in Autoimmune Pathophysiology","volume":"53","author":"Ohnuma","year":"2011","journal-title":"Adv. Clin. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/138955707780059853","article-title":"CD26\/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders","volume":"7","author":"Thompson","year":"2007","journal-title":"Mini-Rev. Med. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cordero, O.J., Rafael-Vidal, C., Varela-Calvi\u00f1o, R., Calvi\u00f1o-Sampedro, C., Malvar-Fern\u00e1ndez, B., Garc\u00eda, S., Vi\u00f1uela, J.E., and Pego-Reigosa, J.M. (2021). Distinctive CD26 Expression on CD4 T-Cell Subsets. Biomolecules, 11.","DOI":"10.3390\/biom11101446"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2741\/4671","article-title":"A Novel Role for CD26\/Dipeptidyl Peptidase IV as a Therapeutic Target","volume":"23","author":"Ohnuma","year":"2018","journal-title":"Front. Biosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2741\/2787","article-title":"The Role of CD26\/Dipeptidyl Peptidase IV in Cancer","volume":"13","author":"Havre","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-06-0361","article-title":"Anti-CD26 Monoclonal Antibody-Mediated G1-S Arrest of Human Renal Clear Cell Carcinoma Caki-2 Is Associated with Retinoblastoma Substrate Dephosphorylation, Cyclin-Dependent Kinase 2 Reduction, P27kip1 Enhancement, and Disruption of Binding to the Extracellular Matrix","volume":"12","author":"Inamoto","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-07-0110","article-title":"Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors","volume":"13","author":"Inamoto","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2017.62","article-title":"First-in-Human Phase 1 of YS110, a Monoclonal Antibody Directed against CD26 in Advanced CD26-Expressing Cancers","volume":"116","author":"Angevin","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_9","first-page":"100178","article-title":"Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma","volume":"2","author":"Nakagawa","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2019.09.010","article-title":"Phase I Study of YS110, a Recombinant Humanized Monoclonal Antibody to CD26, in Japanese Patients with Advanced Malignant Pleural Mesothelioma","volume":"137","author":"Takeda","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6950","DOI":"10.1158\/0008-5472.CAN-05-0647","article-title":"CD26 Regulates P38 Mitogen-Activated Protein Kinase-Dependent Phosphorylation of Integrin \u03921, Adhesion to Extracellular Matrix, and Tumorigenicity of T-Anaplastic Large Cell Lymphoma Karpas 299","volume":"65","author":"Sato","year":"2005","journal-title":"Cancer Res."},{"key":"ref_12","first-page":"2031","article-title":"In Vitro and in Vivo Antitumor Effect of the Anti-CD26 Monoclonal Antibody 1F7 on Human CD30+ Anaplastic Large Cell T-Cell Lymphoma Karpas 299","volume":"7","author":"Ho","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic Factors and Treatment of Patients with T-Cell Non-Hodgkin Lymphoma: The, M.D. Anderson Cancer Center Experience","volume":"103","author":"Liu","year":"2005","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming On-Target, off-Tumour Toxicity of CAR T Cell Therapy for Solid Tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T Cell Therapy in T-Cell Malignancies: Is Success a Low-Hanging Fruit?","volume":"12","author":"Rahbarizadeh","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T Cell Malignancies Using CAR-Based Immunotherapy: Challenges and Potential Solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"765097","DOI":"10.3389\/fimmu.2021.765097","article-title":"Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward","volume":"12","author":"Rahbarizadeh","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_19","first-page":"2183","article-title":"CAR T Cell Therapy: A New Era for Cancer Treatment (Review)","volume":"42","author":"Mohanty","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rinaldi, I., Muthalib, A., Edina, B.C., Wiyono, L., and Winston, K. (2022). Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma. Cancers, 14.","DOI":"10.3390\/cancers14143507"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Barros, L.R.C., Couto, S.C.F., da Silva Santurio, D., Paix\u00e3o, E.A., Cardoso, F., da Silva, V.J., Klinger, P., Ribeiro, P.d.A.C., R\u00f3s, F.A., and Oliveira, T.G.M. (2022). Systematic Review of Available CAR-T Cell Trials around the World. Cancers, 14.","DOI":"10.3390\/cancers14112667"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin\u2019s Lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_23","first-page":"7204","article-title":"Expression of CD26 and Its Associated Dipeptidyl Peptidase IV Enzyme Activity Enhances Sensitivity to Doxorubicin-Induced Cell Cycle Arrest at the G(2)\/M Checkpoint","volume":"61","author":"Aytac","year":"2001","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6600791","article-title":"Effect of CD26\/Dipeptidyl Peptidase IV on Jurkat Sensitivity to G2\/M Arrest Induced by Topoisomerase II Inhibitors","volume":"88","author":"Aytac","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hatano, R., Yamada, T., Madokoro, H., Otsuka, H., Komiya, E., Itoh, T., Narita, Y., Iwata, S., Yamazaki, H., and Matsuoka, S. (2019). Development of Novel Monoclonal Antibodies with Specific Binding Affinity for Denatured Human CD26 in Formalin-Fixed Paraffinembedded and Decalcified Specimens. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0218330"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","article-title":"Different Approaches for Interpretation and Reporting of Immunohistochemistry Analysis Results in the Bone Tissue\u2014A Review","volume":"9","author":"Fedchenko","year":"2014","journal-title":"Diagn. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbrc.2014.10.024","article-title":"A Chimeric Antigen Receptor for TRAIL-Receptor 1 Induces Apoptosis in Various Types of Tumor Cells","volume":"453","author":"Kobayashi","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/bcj.2014.2","article-title":"A Novel Strategy Inducing Autophagic Cell Death in Burkitt\u2019s Lymphoma Cells with Anti-CD19-Targeted Liposomal Rapamycin","volume":"4","author":"Ono","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.1038\/s41598-019-54695-w","article-title":"DPP8 Is a Novel Therapeutic Target for Multiple Myeloma","volume":"9","author":"Sato","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2326-6066.CIR-17-0126","article-title":"Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies","volume":"6","author":"Mamonkin","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08923973.2019.1637889","article-title":"T Cells Expressing CD26-Specific Chimeric Antigen Receptors Exhibit Extensive Self-Antigen-Driven Fratricide","volume":"41","author":"Zhou","year":"2019","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A T-Cell-Directed Chimeric Antigen Receptor for the Selective Treatment of T-Cell Malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ijc.2910580317","article-title":"Therapy of Human T-cell Acute Lymphoblastic Leukaemia in Severe Combined Immunodeficient Mice with Two Different Anti-CD7-saporin Immunotoxins Containing Hindered or Non-hindered Disulphide Cross-linkers","volume":"58","author":"Flavell","year":"1994","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A Phase I\/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains","volume":"18","author":"Wang","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41375-020-0824-y","article-title":"A Novel Chimeric Antigen Receptor Redirecting T-Cell Specificity towards CD26+ Cancer Cells","volume":"35","author":"Zhou","year":"2021","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yamada, K., Hayashi, M., Madokoro, H., Nishida, H., Du, W., Ohnuma, K., Sakamoto, M., Morimoto, C., and Yamada, T. (2013). Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062304"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.4049\/jimmunol.145.12.3963","article-title":"Cell Surface Modulation of CD26 by Anti-1F7 Monoclonal Antibody. Analysis of Surface Expression and Human T Cell Activation","volume":"145","author":"Dang","year":"1990","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2567.1997.00053.x","article-title":"Cross-Linking of CD26 Antibody Induces Tyrosine Phosphorylation and Activation of Mitogen-Activated Protein Kinase","volume":"90","author":"Hegen","year":"1997","journal-title":"Immunology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.143.11.3430","article-title":"1F7, a Novel Cell Surface Molecule, Involved in Helper Function of CD4 Cells","volume":"143","author":"Morimoto","year":"1989","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.2741\/2844","article-title":"Role of CD26\/Dipeptidyl Peptidase IV in Human T Cell Activation and Function","volume":"13","author":"Ohnuma","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.4049\/jimmunol.149.2.481","article-title":"Cloning and Functional Expression of the T Cell Activation Antigen CD26","volume":"149","author":"Tanaka","year":"1992","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"eaay8248","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB Costimulation Promotes CAR T Cell Survival through Noncanonical NF-\u039aB Signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci. Signal."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","article-title":"Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia","volume":"18","author":"Zhao","year":"2020","journal-title":"Mol. Ther.-Oncolytics"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"876758","DOI":"10.3389\/fonc.2022.876758","article-title":"Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies","volume":"12","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1073\/pnas.0400782101","article-title":"A Gene Atlas of the Mouse and Human Protein-Encoding Transcriptomes","volume":"101","author":"Su","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4239\/wjd.v13.i2.85","article-title":"Role of Dipeptidyl Peptidase 4 Inhibitors in the New Era of Antidiabetic Treatment","volume":"13","author":"Florentin","year":"2022","journal-title":"World J. Diabetes"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/16\/2059\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:32:53Z","timestamp":1760128373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/16\/2059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,14]]},"references-count":48,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cells12162059"],"URL":"https:\/\/doi.org\/10.3390\/cells12162059","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,14]]}}}